Additionally, the 36-month beta value for ATAI is 1.48. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for ATAI is 137.08M and currently, short sellers hold a 8.42% ratio of that float. The average trading volume of ATAI on June 23, 2025 was 2.12M shares.
ATAI) stock’s latest price update
ATAI Life Sciences N.V (NASDAQ: ATAI)’s stock price has gone rise by 2305618 in comparison to its previous close of 2.48, however, the company has experienced a 0.42% increase in its stock price over the last five trading days. proactiveinvestors.com reported 2025-06-19 that The psychedelics sector is experiencing a resurgence of optimism in 2025 driven by a more favorable federal government under President Donald Trump’s administration, shifting state-level policies, and encouraging clinical trial results supporting the efficacy of psychedelic therapies. A major setback for the sector was the Food and Drug Administration rejecting Lykos Therapeutics’ MDMA-assisted therapy for post-traumatic stress disorder in August last year.
ATAI’s Market Performance
ATAI Life Sciences N.V (ATAI) has seen a 0.42% rise in stock performance for the week, with a 10.93% gain in the past month and a 46.12% surge in the past quarter. The volatility ratio for the week is 3.35%, and the volatility levels for the past 30 days are at 4.24% for ATAI. The simple moving average for the last 20 days is -7.57% for ATAI’s stock, with a simple moving average of 36.91% for the last 200 days.
Analysts’ Opinion of ATAI
Many brokerage firms have already submitted their reports for ATAI stocks, with H.C. Wainwright repeating the rating for ATAI by listing it as a “Buy.” The predicted price for ATAI in the upcoming period, according to H.C. Wainwright is $10 based on the research report published on November 18, 2024 of the previous year 2024.
Maxim Group, on the other hand, stated in their research note that they expect to see ATAI reach a price target of $6. The rating they have provided for ATAI stocks is “Buy” according to the report published on April 03rd, 2024.
Loop Capital gave a rating of “Buy” to ATAI, setting the target price at $18 in the report published on November 01st of the previous year.
ATAI Trading at 16.21% from the 50-Day Moving Average
After a stumble in the market that brought ATAI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -19.74% of loss for the given period.
Insider Trading
Kirpekar Sahil, the Chief Business Officer of ATAI Life Sciences N.V, sale 48,563 shares at $1.35 during a trade that took place back on Mar 21 ’25, which means that Kirpekar Sahil is holding 115,636 shares at $65,560 based on the most recent closing price.
Stock Fundamentals for ATAI
Current profitability levels for the company are sitting at:
- -53.12 for the present operating margin
- 0.88 for the gross margin
The net margin for ATAI Life Sciences N.V stands at -79.97. The total capital return value is set at -0.59. Equity return is now at value -62.43, with -50.86 for asset returns.
Based on ATAI Life Sciences N.V (ATAI), the company’s capital structure generated 0.09 points at debt to capital in total, while cash flow to debt ratio is standing at -5.46. The debt to equity ratio resting at 0.09. The interest coverage ratio of the stock is -29.66.
Currently, EBITDA for the company is -145.33 million with net debt to EBITDA at 0.23. When we switch over and look at the enterprise to sales, we see a ratio of 211.79. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.07.
Conclusion
In conclusion, ATAI Life Sciences N.V (ATAI) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
